Placental Growth Factor Assessment of Women With Suspected Pre-eclampsia

Status Completed

Clinical Trial Summary

The primary aim is to establish the effectiveness of plasma PlGF measurement in reducing maternal morbidity (with assessment of perinatal safety in parallel) in women presenting with suspected pre-eclampsia prior to 37 weeks' gestation.

The long term aim is to demonstrate that knowledge of PlGF measurement enables appropriate stratification of the antenatal management of women presenting with suspected pre-eclampsia, such that those at highest risk receive greater surveillance with a decrease in maternal adverse outcomes, and those at lower risk can be managed without unnecessary admission and other interventions, such that the results would influence international clinical practice in antenatal patient healthcare

Clinical Trial Description

Pre-eclampsia (PET), a disease of late pregnancy characterised by hypertension and proteinuria, complicates 2-8% of pregnancies and is associated with significant maternal and neonatal morbidity and mortality. Many reports have highlighted the frequent substandard care, often attributed to clinicians not identifying the seriousness of clinical signs suggestive of the disease. Consequently, improvements in prediction of development of PET have the potential to vastly improve clinical outcomes and reduce costs.

Placental Growth Factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family and represents a key regulator of angiogenic events in pathological conditions. PlGF exerts its biological function through the binding and activation of the receptor Flt-1. In PET, it is thought that endothelial dysfunction leads to an increased level of a circulating decoy receptor, known as soluble Flt-1, (sFlt-1), a soluble receptor for both VEGF-A and PlGF.

In 2013, the INFANT team were part of an international group that published the first multicentre prospective study (PELICAN) evaluating the use of PlGF in women presenting with suspected PET, which reported high sensitivity (95-96%) and negative predictive value (95-98%) for low PlGF in determining need for delivery for confirmed PET within 14 days. This study suggests that PlGF testing presents a realistic and innovative adjunct to the management of women with suspected PET, especially those presenting preterm. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02881073
Study type	Interventional
Source	Irish Centre for Fetal and Neonatal Translational Research
Contact
Status	Completed
Phase	N/A
Start date	June 29, 2017
Completion date	April 26, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03299777` - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan	N/A
Completed	`NCT03650790` - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies	N/A
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT03302260` - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial	N/A
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Completed	`NCT01911494` - Community Level Interventions for Pre-eclampsia	N/A
Terminated	`NCT02025426` - Phenylephrine Versus Ephedrine in Pre-eclampsia	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Active, not recruiting	`NCT02031393` - Establishing First Trimester Markers for the Identification of High Risk Twin	N/A
Terminated	`NCT00141310` - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia	Phase 2
Completed	`NCT00157521` - L-Arginine in Pre-Eclampsia	Phase 3
Completed	`NCT04795154` - Prenatal Yoga as Complementary Therapy of Preeclampsia	N/A
Completed	`NCT00004399` - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	N/A
Completed	`NCT00005207` - Renin and Prorenin in Pregnancy	N/A
Recruiting	`NCT04551807` - Natural Versus Programmed Frozen Embryo Transfer (NatPro)	Phase 3
Terminated	`NCT04092829` - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer	N/A
Recruiting	`NCT06067906` - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients	N/A
Recruiting	`NCT06317467` - Role of Anti-C1q Autoantibodies in Pregnancy
Completed	`NCT02218931` - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes	N/A
Active, not recruiting	`NCT04484766` - Preeclampsia Associated Vascular Aging

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Placental Growth Factor Assessment of Women With Suspected Pre-eclampsia — PARROT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms